8-K/A: Travere Therapeutics Reports Strong First Quarter 2025 Financial Results Driven by FILSPARI Sales

Travere Therapeutics announces positive Q1 2025 financial results, highlighted by a 182% year-over-year increase in FILSPARI U.S. net product sales and progress in expanding FILSPARI's indications.

Summary

• Travere Therapeutics reported its first quarter 2025 financial results on May 1, 2025.
• Net product sales for Q1 2025 were $75.9 million, compared to $40.0 million for the same period in 2024, driven by the commercial launch of FILSPARI in IgAN.
• FILSPARI U.S. net product sales totaled $55.9 million in Q1 2025.
• The company received 703 new patient start forms (PSFs) for FILSPARI in Q1 2025.
• R&D expenses for Q1 2025 were $46.9 million, compared to $49.4 million for the same period in 2024.
• SG&A expenses for Q1 2025 were $72.8 million, compared to $64.2 million for the same period in 2024.
• Net loss for Q1 2025 was $41.2 million, or $0.47 per basic share, compared to a net loss of $136.1 million, or $1.76 per basic share for the same period in 2024.
• As of March 31, 2025, the company had cash, cash equivalents, and marketable securities of $322.2 million.
• The company submitted an sNDA seeking priority review for traditional approval of FILSPARI in FSGS in Q1 2025.
• The company expects a PDUFA target action date of August 28, 2025, for its sNDA requesting modification of liver monitoring and removal of embryo-fetal toxicity monitoring REMS for FILSPARI.
• The European Commission converted conditional marketing authorization (CMA) of FILSPARI to standard marketing authorization (MA) for the treatment of adults with primary IgAN in Europe in April 2025.
• The company expects to receive a $17.5 million milestone payment from CSL Vifor in the second quarter of 2025 related to the European approval.
• The UK Medicines and Healthcare products Regulatory Agency (MHRA) converted the conditional FILSPARI approval to standard approval for treatment of adults with primary IgAN in April 2025.
• The company is on track to restart enrollment in the Phase 3 HARMONY Study for Pegtibatinase in 2026.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, regulatory approvals, and clinical progress. The company is well-positioned for future growth, although risks associated with regulatory approvals and market competition remain.

Positives

• Significant increase in net product sales driven by FILSPARI.
• FILSPARI achieved full approval in Europe and the UK.
• Submission of sNDA for FILSPARI in FSGS indicates potential expansion of its market.
• Strong cash position provides financial stability.
• Positive clinical data presented at the National Kidney Foundation Spring Clinical Meetings reinforces FILSPARI's position in IgAN and potential in FSGS.
• The company is on track to restart enrollment in the Phase 3 HARMONY Study in 2026.

Negatives

• SG&A expenses increased due to investment in the commercial launch of FILSPARI.
• Net loss, although significantly reduced compared to the previous year, still indicates ongoing losses.
• The company is reliant on the FDA accepting the sNDA for filing, granting priority review of the sNDA or granting approval of FILSPARI for FSGS on the anticipated timeline, or at all.

Risks

• The company's sNDA for FILSPARI in FSGS may face regulatory hurdles.
• Clinical trials may not succeed or may be delayed for safety, regulatory or other reasons.
• Market acceptance of FILSPARI depends on efficacy, safety, price, reimbursement, and benefit over competing therapies.
• The company faces risks associated with the ongoing commercial launch of FILSPARI in IgAN.
• The company faces risks associated with the timing and potential outcome of its and its partners clinical studies.
• The company faces risks associated with the challenges of manufacturing scale-up.
• The company faces risks associated with the successful development and execution of commercial strategies for such products, including FILSPARI.
• The company faces risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations.
• The company faces the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions.
• The company faces uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties.
• The company faces risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the company's products, and technological changes that may limit demand for the company's products.

Future Outlook

The company anticipates continued progress with the FILSPARI launch in IgAN, potential approval of FILSPARI for FSGS, and restart of enrollment in the Phase 3 HARMONY Study in 2026. They also expect to receive a $17.5 million milestone payment from CSL Vifor in the second quarter of 2025.

Management Comments

• Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics, stated that FILSPARI is elevating the standard of care in IgAN.
• Eric Dube noted the strong start to the year, reflecting leadership in the IgAN space.
• Eric Dube mentioned encouraging signs of a broader shift toward earlier treatment and lower proteinuria goals, which they believe will further amplify FILSPARI's growth potential.
• Eric Dube stated that the company is well-positioned to deliver sustainable growth for all stakeholders.

Industry Context

Travere Therapeutics is focused on rare kidney diseases, specifically IgAN and FSGS. The company's FILSPARI is positioned as a key therapy in these areas, competing with existing treatments and aiming to become the standard of care. The conversion of conditional approvals to standard approvals in Europe and the UK, along with the potential approval in FSGS, would strengthen its market position.

Comparison to Industry Standards

• FILSPARI is being positioned as a replacement for the historical standard of care in IgAN, indicating a potential shift in treatment paradigms.
• The company is comparing FILSPARI's efficacy to irbesartan in FSGS, highlighting earlier and more frequent proteinuria remission.
• The company's focus on kidney-targeted therapies aligns with the growing trend of precision medicine in nephrology.
• Competitors in the IgAN space include Calliditas Therapeutics with Tarpeyo (budesonide) and other companies developing novel therapies.
• In FSGS, if approved, FILSPARI would be the first and only approved medicine indicated for FSGS, a rare kidney disorder and a leading cause of kidney failure.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive financial results and pipeline progress.
• Patients: Access to new and potentially life-changing therapies for rare kidney diseases.
• Employees: Job security and growth opportunities within the company.
• Partners: Continued collaboration and potential for increased revenue through partnerships.

Next Steps

• Receive notice regarding the acceptance and timeline for sNDA review from the FDA for FILSPARI in FSGS.
• Potential FDA approval of FILSPARI for FSGS.
• Receive a $17.5 million milestone payment from CSL Vifor in the second quarter of 2025.
• Renalys Pharma expects topline results from its registrational Phase 3 clinical trial of sparsentan for the treatment of IgAN in Japan in the second half of 2025.
• Restart enrollment in the Phase 3 HARMONY Study for Pegtibatinase in 2026.

Key Dates

Keywords

FILSPARI, Travere Therapeutics, IgAN, FSGS, Financial Results, sparsentan, Pegtibatinase, TVTX